胃癌患者术前贫血与术后并发症及预后的相关性

目的:探讨术前贫血和贫血程度与胃癌并发症及预后的关系.方法:对2008年10月至2016年11月期间空军军医大学西京医院消化外科3692例行胃癌根治术患者的临床资料进行分析.探索术前贫血和贫血程度对胃癌术后并发症和预后的影响.结果:3692例患者中,男性2889例(78.3％),女性803例(21.7％).贫血患者14...     

肿瘤堆积物对胃癌手术患者生存状况的影响

目的探讨肿瘤堆积物(TDs)对胃癌手术患者生存状况的影响。方法将60例行胃癌根治手术的患者按照病理检查结果分为TDs阳性组20例与TDs阴性组40例,比较2组患者术后生存状况。结果 TDs阳性组肿瘤大小、未分化型胃癌占比、淋巴结转移个数、并发症发生率及TNMⅢ期占比等均显著高于TDs阴性组,差异有统计学意义(P<0.05);TDs阳性组术后3年、5年的生存率显著低于TDs阴性组,差异有统计学意义(P<0.05)。结论肿瘤堆积物阳性患者的术后生存状况差,可作为胃癌患者术后生存状况的判断指标。     

营养素与胃癌患者生存质量的相关性分析

目的通过胃癌术后存活患者的营养素调查,提供胃癌患者康复时期科学信息.方法选择84例胃癌患者术后仍存活1年以上患者为调查对象,自行编制调查表,内容包括:一般情况及膳食摄入量情况;生存质量设20个问题.统计采用描述分析和线性回归分析.结果本组84例胃癌患者生存质量总分平均值为68.85分,营养素均未达标,硒达标率最低(5.09%),影响生存质量的有统计学意义营养素为热能、蛋白质、钙、铁等8种.结论胃癌患者的原来体质差,免疫力低,提供合理营养素利于提高患者的体质和免疫水平,可提高生存质量.     

青海地区胃癌相关性贫血的临床研究

目的：通过青海地区胃癌患者的贫血状况的分析,明确本地区贫血与胃癌分期及化疗效果的相关性。方法：收集2004年6月到2008年4月来院治疗的胃癌患者258例,检查血常规以了解贫血的状况,分析贫血发生率与肿瘤分期的关系。跟踪病例化疗情况,分析化疗后贫血发生率及其与预后间的关系。结果：样本中贫血发生率为43.8%。其中女性中为51.8%;男性中为41.6%,无显著性差异。在258例病人中具有完整TNM分期的195例,胃癌患者的贫血发生率根据肿瘤分化程度、肿瘤分期、浸润深度、淋巴结转移、远处转移、肿瘤大小、年龄不同有显著性差异。肿瘤在胃贲门区、胃体部、胃窦区贫血发生率无显著性差异。258例胃癌患者接受三周期化疗后,贫血病人为161例。其中化疗后出现贫血的病人有46例,疾病控制率（DCR）为78.26%,客观缓解率（ORR）为21.74%。而化疗后无贫血的17例病人,疾病控制率（DCR）94.12%,客观缓解率（ORR）为52.94%。贫血组和非贫血组的DCR和ORR有显著性差异。在化疗过程中,15例病人接受了输血治疗,没有关于铁剂及促红细胞生成素（Erythropoietin,EPO）治疗的记录。结论：按NCI标准判断,青海地区胃癌相关性贫血的发生率与国内其他地区发生率相近。胃癌相关性贫血的发生率与肿瘤分化程度、肿瘤分期、浸润深度、淋巴结转移、远处转移、肿瘤大小、年龄有关。化疗过程中发生贫血的病人对化疗的反应差,化疗过程中未发生贫血的病人疗效较好。本研究中贫血的发生率与患者性别及肿瘤的部位无关。     

青海地区胃癌相关性贫血的临床研究

目的:通过青海地区胃癌患者的贫血状况的分析,明确本地区贫血与胃癌分期及化疗效果的相关性。方法:收集2004年6月到2008年4月来院治疗的胃癌患者258例,检查血常规以了解贫血的状况,分析贫血发生率与肿瘤分期的关系。跟踪病例化疗情况,分析化疗后贫血发生率及其与预后间的关系。结果:样本中贫血发生率为43.8%。其中女性中为51.8%;男性中为41.6%,无显著性差异。在258例病人中具有完整TNM分期的195例,胃癌患者的贫血发生率根据肿瘤分化程度、肿瘤分期、浸润深度、淋巴结转移、远处转移、肿瘤大小、年龄不同有显著性差异。肿瘤在胃贲门区、胃体部、胃窦区贫血发生率无显著性差异。258例胃癌患者接受三周期化疗后,贫血病人为161例。其中化疗后出现贫血的病人有46例,疾病控制率(DCR)为78.26%,客观缓解率(ORR)为21.74%。而化疗后无贫血的17例病人,疾病控制率(DCR)94.12%,客观缓解率(ORR)为52.94%。贫血组和非贫血组的DCR和ORR有显著性差异。在化疗过程中,15例病人接受了输血治疗,没有关于铁剂及促红细胞生成素(Erythropoietin,EPO)治疗的记录。结论:按NCI标准判断,青海地区胃癌相关性贫血的发生率与国内其他地区发生率相近。胃癌相关性贫血的发生率与肿瘤分化程度、肿瘤分期、浸润深度、淋巴结转移、远处转移、肿瘤大小、年龄有关。化疗过程中发生贫血的病人对化疗的反应差,化疗过程中未发生贫血的病人疗效较好。本研究中贫血的发生率与患者性别及肿瘤的部位无关。     

胃癌患者生存状况与幽门螺杆菌感染情况的关系

目的 探讨幽门螺杆菌感染与胃癌患者生存状况的关系.方法 回顾性分析98例胃癌患者的临床资料,根据是否发生幽门螺杆菌感染分为感染组(n=67)和非感染组(n=31),分析胃癌发病的危险因素及幽门螺杆菌感染情况对胃癌患者生存情况的影响.结果 感染组有消化道肿瘤家族史患者的比例高于非感染组患者,差异有统计学意义(P<0.05).随访6～36个月,感染组患者死亡36例,生存率为46.3％,中位生存时间为32个月;非感染组患者死亡10例,生存率为67.7％;非感染组患者的生存情况优于感染组,差异有统计学意义(χ2=4.119,P=0.042).Cox比例风险模型分析结果表明,年龄、幽门螺杆菌感染是影响胃癌患者生存情况的危险因素(OR>1,P<0.05);直系亲属无消化道肿瘤家族史是胃癌患者生存情况的保护因素(OR<1,P<0.01).结论 幽门螺杆菌感染且直系亲属有消化道肿瘤家族史患者患胃癌的可能性更高;年龄、幽门螺杆菌感染是影响胃癌患者生存情况的危险因素;直系亲属无消化道肿瘤家族史是胃癌患者生存情况的保护因素.幽门螺杆菌阴性胃癌患者生存情况优于幽门螺杆菌阳性胃癌患者.     

外周血中生存素的表达与胃癌预后的相关研究

通过检测外周血中生存素来判断是否能预测胃癌的复发与转移。方法：以反转录-聚合酶链式反应-酶联免疫测定（RT-PCR-ELISA）方法检测胃癌患者外周血中生存素mRNA的表达,分析其与临床病理因素之间的关系。对部分患者进行36个月随访,分析复发及转移时间与外周血中生存素mRNA的表达之间的关系。结果：53例胃癌外周血中32例（60.4%）生存素mRNA表达阳性。肿瘤大小>5cm及≤5cm生存素mRNA表达率分别为78.3%、46.0%。浸润深度达浆膜层者外周血生存素mRNA表达率74.2%,高于侵及黏膜下层及肌层的表达率（33.3%）,淋巴结有转移者外周血表达率为75.0%,高于无淋巴结转移的表达率（29.4%）。通过随访研究发现外周血生存素阳性的患者复发及转移率明显高于阴性患者。结论：生存素mRNA在外周血的表达与肿瘤大小、浸润深度、淋巴结转移和临床分期均有明显相关性,但与肿瘤部位、分化程度无明显相关。并可用于提示患者复发与转移风险。外周血生存素的表达可作为评价胃癌生物学行为及预后的参考指标。     

胃癌组织中EphA1的表达与肿瘤转移及患者生存时间的关系

背景与目的:受体酪氨酸激酶Eph基因家族在生长发育和肿瘤发生中发挥重要作用.本课题研究EphA1在胃癌中的表达,并分析其与临床病理指标之间的联系,旨在探索EphA1基因在胃癌发生中的作用.方法:利用实时定量逆转录聚合酶链式反应(real time RT-PCR)检测胃癌组织和正常黏膜中EphA1转录子的表达.通过甲基化特异性PCR检查启动子区相关的CpG岛甲基化状态.并运用免疫组织化学染色测定细胞的EphA1蛋白表达水平.结果:EphA1转录子在34%(19/56)的样本中表达下调,25%(14/56)的样本中表达上调,41%(23/56)的样本中表达差异无统计学意义(P＞0.05).EphA1转录子表达水平与肿瘤大小(P=0.05)、分期(P=0.001)以及淋巴结转移(P=0.011相关.在检查的15例EphA1下调的标本中,12例检出甲基化EphA1 DNA;在5例上调的标本中,仅1例检出甲基化DNA;18例表达无差异的标本中,3例检出甲基化DNA(P=0.001).145例组织标本中EphA1蛋白表达与转录子表达的临床意义相符.随访89例患者分析生存时间发现,EphA1下调者预后比上调者长(P=0.005).结论:EphA1可能在胃癌细胞的侵袭和转移中发挥作用.     

幽门螺杆菌感染与胃癌患者临床特征和生存状况的关系研究

目的：探究幽门螺杆菌（HP）感染与胃癌患者临床特征和生存状况的关系。方法选择就诊的80例胃癌患者,根据患者是否发生HP感染分为感染组患者52例和未感染组患者28例,根据感染组患者的HP感染量又将患者分为A、B、C三组,比较四组患者的临床特征和生存状况。结果四组患者的年龄,淋巴结转移,Lauren分型,局部浸润方面比较,差异均有统计学意义（P﹤0.05）。C组患者淋巴结转移N2期和N3期例数多于其他三组,而未感染组N0、N1期例数较多;C组患者Lauren分型中肠型比例,局部浸润T3、T4期比例大于其他三组;感染组患者胃窦癌比例较大,未感染组患者中胃底癌比例较大,差异均有统计学意义（P﹤0.05）。对照组患者的平均生存期大于感染组,差异具有统计学意义（P﹤0.05）,且感染组患者中HP感染量越大患者生存期越短。Cox回归分析显示,HP感染,淋巴结转移,年龄（﹥60岁）,胃窦癌,浸润深度均是影响胃癌患者生存状况的独立危险因素,具有统计学意义（P﹤0.05）。结论 HP感染与胃癌患者的临床特征有关,且HP感染量越大患者的生存状况越差。     

HER-2、贫血和前白蛋白与胃癌预后的关系

目的研究HER-2、术前贫血和前白蛋白水平与胃癌预后的关系。方法对2008年1月-2009年12月经手术病理确诊、有完整随访资料的103例Ⅲ～Ⅳ期胃癌患者进行回顾性分析。选择性别、年龄、组织学类型、肿瘤部位、肿瘤大小、浸润深度、临床分期、HER-2、术前血红蛋白和血清前白蛋白水平作为观察指标。采用Kaplan-Meier生存分析、Log rank 检验和Cox 比例风险模型进行单因素和多因素分析;组间变量采用χ²检验或Fisher's精确检验。结果单因素分析显示N分期、HER-2、贫血、临床分期、前白蛋白水平均与胃癌的预后显著相关(P<0.05);年龄、性别、肿瘤大小和部位与胃癌生存无相关性。Cox多因素分析显示HER-2过表达、贫血、白蛋白水平和临床分期是影响胃癌预后的独立因素(P<0.05)。结论（1）临床分期、HER-2、贫血和前白蛋白是胃癌的独立预后因素; （2）淋巴结转移与胃癌预后相关,但不是独立预后因素。（3）贫血的构成比与HER-2状态及临床分期有关,与前白蛋白无关。     

Impact of prior cancer history on survival of patients with gastric cancer

BackgroundPatients with prior cancer history are commonly excluded from clinical trial. However, the impact of prior cancer on survival of patients with gastric cancer remains largely unknown. The aim of this study was to evaluate the prevalence of prior cancer and assess its impact on survival of patients diagnosed with gastric cancer.MethodsPatients with gastric cancer as the primary or second primary malignancies diagnosed from 2004 to 2010 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM) was conducted to balance baseline characteristics. Kaplan-Meier method, multivariate Cox proportional hazard model, and multivariate competing risk model were performed for survival analysis.ResultsA total of 28,795 eligible patients with gastric cancer were included, of whom 2695 (9.35%) had a history of prior cancer. Prostate (35%), breast (12%), colon (8%), and urinary bladder (7%) malignancies were the most common prior cancer types. Patients with prior cancer history had slightly inferior overall survival (AHR = 1.06; 95% CI [1.00–1.12]; P = 0.043) but superior gastric cancer-specific survival (AHR = 0.82; 95% CI [0.76–0.88]; P < 0.001) compared with those without prior cancer. The subgroup analysis determined that a prior cancer history did not adversely affect gastric patients’ clinical outcomes, except in those with prior cancer diagnosed within one year, at distant stage, or originating from lung and bronchus.ConclusionA substantial proportion of gastric cancer patients with a history of prior cancer had non-inferior clinical outcome to those without prior cancer. These patients should be considered in clinical trials.     

血浆Ｄ-二聚体水平与转移性胃癌患者生存期的关系

目的　探讨血浆Ｄ-二聚体水平与转移性胃癌患者生存期的关系。方法　搜集自２００６年１０月至２００８年１０月于我科治疗的转移性胃癌患者血浆Ｄ-二聚体的数据,结合其他临床病理参数,分析其水平与生存期的关系。结果　共有８２例患者入组,其中男性５２例,女性３０例,平均年龄５７岁。血浆Ｄ-二聚体正常（＜３００μｇ／Ｌ）４８例,升高（≥３００μｇ／Ｌ）３４例。Ｄ-二聚体正常组和升高组中位生存期分别为１０.９个月（９５％ＣＩ：９.１～１２.７个月）和６９个月（９５％ＣＩ：４.９～８.８个月）,两组间的差异有统计学意义（Ｐ＜０.００１）。结论　血浆Ｄ-二聚体升高的转移性胃癌患者生存期明显短于血浆Ｄ-二聚体正常者,血浆Ｄ-二聚体在一定程度上可以作为转移性胃癌患者的预后指标。     

老年人胃癌术后生存分析研究

目的探讨老年人胃癌术后的生存情况及其影响因素。方法回顾性分析收治并行胃癌切除手术的96例患者的临床资料及随访资料。结果胃癌患者术后1、3、5年生存率分别为74.0%、57.3%和19.8%,所有患者的中位生存时间为46.4个月;Log-rank比较分析显示,年龄(2=2.96,P<0.05)、饮酒史(2=9.42,P<0.05)、胃癌转移(2=10.34,P<0.05)、组织学分化程度较高(2=8.83,P<0.05)、浸润程度到达浆膜(2=12.21,P<0.05)等因素对胃癌1、3、5年生存率具有显著影响;Cox回归模型分析显示,饮酒史(RR=1.86,95%CI:1.21².64)、胃癌转移(RR=1.89,95%CI:1.172.64)、胃癌转移(RR=1.89,95%CI:1.17².55)、组织学分化程度低(RR=2.02,95%CI:1.372.55)、组织学分化程度低(RR=2.02,95%CI:1.37².85)、浸润程度到达浆膜(RR=2.18,95%CI:1.292.85)、浸润程度到达浆膜(RR=2.18,95%CI:1.29³.01)是影响胃癌术后生存时间的独立因素。结论有饮酒史、术前癌症转移、组织分化程度低、浸润程度较深会影响老年人胃癌术后生存时间。     

Surgical margins in gastric cancer T2 and T3 and its relationship with recurrence and overall survival at 5 years

IntroductionSurgical resection is the potentially curative treatment in gastric cancer. However, definitive surgical margins are controversial.Material and methodsWe conducted a retrospective, observational study. All patients with gastric cancer treated with surgery of T2 and T3, tumors without involvement of the esophagogastric junction and without neoadjuvant treatment were included.ResultsA total of 70 patients were included. 44 men (62.9%) and 26 women (37.1%). In multivariate analysis, depth of the invasion (T2 vs T3), lymphadenectomy and more than 5 positive nodes were independent factors for recurrence at 5 years. Depth of the invasion (T2 vs T3), intra-abdominal metastases and recurrence were independent factors of overall survival at 5 years. ROC analysis did not show a definitive surgical margin with better 5-year overall survival and lower recurrence.ConclusionsIn patients with gastric cancer T2 and T3, surgical margin did not affect 5-year overall survival or recurrence rate. Other factors are associated with recurrence and 5-year overall survival at 5 years, regardless of the distance from the tumor to the margin.     

血浆D-二聚体水平与转移性胃癌患者生存期的关系

Objective:The principal purpose of this study was to determine the relationship between level of plasma D-dimer and survival time in metastatic gastric cancer patients.Methods:We retrospectively collected the data of plasma D-dimer in metastatic gastric cancer patients admitted in our Department (Department of Oncology,The Affiliated Changzheng Hospital,The Second Military Medical University,Shanghai,China) from October 2006 to October 2008 and analyzed the relationship between level of plasma D-dimer and s...     

大规模中国人胃癌组织芯片的构建及胃癌预后因素的分析

目的：利用组织芯片技术研究影响中国人胃癌患者预后的临床病理及生物学因素。方法：收集1072例胃癌手术切除标本构建组织芯片,结合免疫组化,检测p53和PCNA的表达,并用Kaplan-Meier分析和多因素Cox回归等统计方法分析影响中国人胃癌患者预后的相关因素。结果：成功构建了含有1072例胃癌信息的组织芯片,p53和PCNA在胃癌中的表达率显著高于正常组织中的表达,分别为55．1％和89．3％,进展期胃癌中的表达率显著高于早期胃癌。p53的过度表达与年龄、男性、贫血、腺癌、分化、浆膜侵犯和淋巴结转移高度相关,而PCNA则与年龄、肿瘤部位、腺癌、分化、浆膜侵犯、淋巴结转移以及TNM高度相关。单因素分析中,年龄、贫血、肿瘤大小、分化、肿瘤分期、侵犯深度、淋巴结转移、手术方式、切缘、术中输血以及PCNA均与预后相关,而在Cox回归多因素分析中,年龄、肿瘤分化、分期、淋巴结转移、手术方式、术中输血以及PCNA与预后相关。结论：1072例胃癌的大规模组织芯片为胃癌的深入研究构建了一个良好的技术平台;胃癌患者的机体情况、肿瘤、手术情况和生物学因素在内的综合因素影响了其预后.     

Factors affecting survival in operated gastric cancer

In this study, our aim was to determine the possible effects of Helicobacter pylori (HP), chronic atrophic gastritis (CAG), and gastrointestinal metaplasia (GIM) on survival in operated bowel type gastric cancer patients (INT-GC). Among 548 patients, 347(63.3%) were male. The median age was 57 years. Disease-free survival (DFS) and overall survival (OS) were significantly shorter in patients with GIM than those in patients without GIM (log rank, P = 0.003 and log rank P = 0.003, respectively). Multivariate analysis showed that presence of GIM (HR, 2.1) was found to be an independent factor of worse DFS. In our study, stage pIII patients with GIM had significantly shorter DFS and OS than those without GIM (log rank p = 0.008 and log rank p = 0.001, respectively). However, in subgroup analysis of patients with GIM, there was no significant DFS and OS difference between patients with stage pI and pII disease (log rank p = 0.999, log rank p = 0.184 vs. log rank p = 0.409, log rank p = 0.281, respectively).     

影响胃癌腹腔脱落癌细胞阳性率的临床病理因素分析

目的探讨胃癌患者腹腔脱落癌细胞阳性率与临床病理因素之间的关系。方法回顾性分析行胃癌手术的100例患者,开腹后取腹腔冲洗液500mL,检测腹腔脱落癌细胞的阳性率,分析腹腔脱落癌细胞阳性率与临床病理因素之间的关系。结果100例胃癌患者腹腔冲洗液中检测到癌细胞20例,阳性率20％。单因素分析显示,患者年龄、肿瘤大小、肿瘤侵犯深度、组织学分型是影响腹腔脱落癌细胞阳性率的危险因素;多因素Logistic回归分析显示,肿瘤侵犯深度、组织学分型是影响腹腔脱落癌细胞阳性率的独立危险因素。结论腹腔脱落癌细胞是胃癌病人发生腹膜转移的重要因素,其I临床病理特征影响腹腔脱落癌细胞阳性率。     

Textbook outcome and survival after gastric cancer resection with curative intent: A population-based analysis

BackgroundThe concept of textbook outcome (TO) has been proposed for analyzing quality of surgical care. This study assessed the incidence of TO among patients undergoing curative gastric cancer resection, predictors for TO achievement, and the association of TO with survival.MethodAll patients with gastric and gastroesophageal junction cancers undergoing curative gastrectomy between January 2014–December 2017 were identified from a population-based database (Spanish EURECCA Registry). TO included: macroscopically complete resection at the time of operation, R0 resection, ≥15 lymph nodes removed and examined, no serious postoperative complications (Clavien-Dindo ≥II), no re-intervention, hospital stay ≤14 days, no 30-day readmissions and no 90-day mortality. Logistic regression was used to assess the adjusted achievement of TO. Cox survival regression was used to compare conditional adjusted survival across groups.ResultsIn total, 1293 patients were included, and TO was achieved in 541 patients (41.1%). Among the criteria, “macroscopically complete resection” had the highest compliance (96.5%) while “no serious complications” had the lowest compliance (63.7%). Age (OR 0.53 for the 65–74 years and OR 0.34 for the ≥75 years age group), Charlson comorbidity index ≥3 (OR 0.53, 95%CI 0.34–0.82), neoadjuvant chemoradiotherapy (OR 0.24, 95%CI 0.08–0.70), multivisceral resection (OR 0.55, 95%CI 0.33–0.91), and surgery performed in a community hospital (OR 0.65, CI95% 0.46–0.91) were independently associated with not achieving TO. TO was independently associated with conditional survival (HR 0.67, 95%CI 0.55–0.83).ConclusionTO was achieved in 41.1% of patients who underwent gastric cancer resection with curative intent and was associated with longer survival.     

An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone

PURPOSE: Surgical resection is the mainstay of therapy for patients presenting with Stage I and II non-small-cell lung cancer (NSCLC). Despite optimal staging and surgery, these patients are still at significant risk for failure. The purpose of this study is to report a retrospective analysis of the outcome of patients treated with surgery alone, as well as to analyze prognostic factors associated with survival. MATERIALS AND METHODS: From May 2000 to November 2002, there was a total of 125 patients who were treated with surgery for NSCLC at University of Maryland Medical Center. Of these, 82 Stage I and II patients who received surgery alone as the definitive therapy were identified. The median age of the entire cohort was 68 years (range, 43-88 years). There were 48 males and 34 females. Sixty-three patients (76.8%) underwent lobectomies whereas 19 patients (23.2%) underwent nonlobectomy (wedge resection or segmentectomy) procedures. Patients who received neoadjuvant or adjuvant radiation therapy or chemotherapy were excluded from the study. Factors included in univariate and multivariate analyses were age, sex, tumor histology, pathologic stage, p53 status, preoperative hemoglobin (Hgb), and type of surgery performed. Endpoints of the study were relapse-free survival (RFS) and overall survival (OS). RESULTS: Median follow-up was 20.8 months (range, 0.4-43.2 months). For the entire cohort, the 2-year RFS was 66.0% and 2-year OS was 76.3%. Median survival for the entire cohort has not been achieved. In univariate analysis, the only factor that achieved statistical significance was preoperative Hgb level. Patients who had preoperative Hgb <12 mg/dL experienced significantly worse RFS (mean RFS: 26.6 months vs. 34.9 months, p = 0.043) and OS (median OS: 27 months vs. 42.5 months, p = 0.011). For Stage I patients (n = 72), the 2-year RFS and OS were 66.4% and 77.1%, respectively. In the subgroup of stage IA patients (n = 37), there was a trend toward decreased overall survival in the anemic patients (2-year OS of 65.6% vs. 90.9%, p = 0.07). For Stage II patients (n = 10), the 2-year RFS and OS were 60.0% and 66.7%. In the Cox multivariate regression analysis, the only factor that achieved statistical significance was preoperative Hgb, with patients with Hgb <12 mg/dL having decreased RFS (RR 4.1, p = 0.020) and OS (RR 2.9, p = 0.026). There was a trend toward worse RFS (p = 0.056) and OS (p = 0.068) in p53-negative patients (n = 39). Stage, histologic type, type of surgery performed, age, and sex did not affect outcome. CONCLUSIONS: In our cohort of mostly Stage I NSCLC patients treated with surgery only, preoperative Hgb <12 mg/dL predicted for worse outcome. This effect was observed even in the traditionally low-risk subgroup of completely resected stage IA patients. Much has been written in the literature about anemia causing possible worsening of tumor hypoxia within solid tumors, thereby increasing radio-resistance. This has been a popular argument to explain poorer outcomes of anemic patients with solid tumors who undergo radiotherapy. However, our data suggest that anemia may be a sign of a more aggressive tumor that is at an increased risk of failure independent of the treatment modality.